Pulse Biosciences (NASDAQ:PLSE) Shares Down 7.3% - Here's What Happened

Key Points

• Pulse Biosciences shares fell 7.3% to about $49.38 in mid-day trading, with volume down 73% from the average session. The stock has risen above its 50-day and 200-day moving averages despite the decline.
• Recent quarterly results missed expectations: the company reported a loss of $0.36 per share versus the expected $0.29 loss, while revenue of $0.43 million came in below the $0.53 million forecast.
• Analyst sentiment remains mixed but leans positive, with four Buy ratings and one Sell rating producing a “Moderate Buy” consensus and a $45.25 average price target. An insider also purchased approximately $50,000 of shares, while institutional investors own 76.95% of the company.

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) traded down 7.3% during mid-day trading on Tuesday . The company traded as low as $50.48 and last traded at $49.3790. Approximately 97,929 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 359,392 shares. The stock had previously closed at $53.24.

Wall Street Analyst Weigh In

PLSE has been the topic of several recent research reports. Wall Street Zen raised Pulse Biosciences from a "sell" rating to a "hold" rating in a research report on Sunday. Mizuho set a $45.00 price objective on shares of Pulse Biosciences in a research report on Monday, August 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Needham & Company LLC began coverage on shares of Pulse Biosciences in a research note on Monday, August 17th. They set a "buy" rating and a $58.00 price objective on the stock. Finally, Canaccord Genuity Group boosted their target price on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Pulse Biosciences has an average rating of "Moderate Buy" and a consensus price target of $45.25.

Pulse Biosciences Stock Down 7.0%

The firm has a 50 day moving average price of $38.45 and a two-hundred day moving average price of $28.25. The company has a market capitalization of $3.43 billion, a price-to-earnings ratio of -41.95 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to analysts' expectations of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. Analysts predict that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Insider Transactions at Pulse Biosciences

In other Pulse Biosciences news, COO Liane Teplitsky acquired 1,001 shares of the company's stock in a transaction on Tuesday, September 1st. The shares were bought at an average cost of $49.95 per share, for a total transaction of $49,999.95. Following the acquisition, the chief operating officer directly owned 4,095 shares of the company's stock, valued at $204,545.25. This trade represents a 32.35% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders purchased 4,095 shares of company stock worth $199,931. 74.00% of the stock is owned by insiders.

Institutional Trading of Pulse Biosciences

A number of hedge funds have recently made changes to their positions in PLSE. Russell Investments Group Ltd. increased its stake in shares of Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company's stock worth $70,000 after buying an additional 619 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock valued at $26,000 after acquiring an additional 680 shares during the last quarter. Osterweis Capital Management Inc. acquired a new position in Pulse Biosciences during the 2nd quarter worth $28,000. Alliancebernstein L.P. grew its holdings in Pulse Biosciences by 6.7% during the 3rd quarter. Alliancebernstein L.P. now owns 20,620 shares of the company's stock worth $365,000 after acquiring an additional 1,300 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock worth $44,000 after purchasing an additional 2,156 shares during the last quarter. Institutional investors and hedge funds own 76.95% of the company's stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.